Portal de Periódicos da CAPES

Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

2014; Elsevier BV; Volume: 123; Issue: 23 Linguagem: Inglês

10.1182/blood-2013-12-542464

1528-0020

Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Willis H. Navarro, John E. Levine, J. Philip Miller, Bronwen E. Shaw, Paul V. O’Donnell, Navneet S. Majhail, Dennis L. Confer,

Hemoglobinopathies and Related Disorders

Key Points BM donors have a threefold higher risk for life-threatening, serious unexpected, or chronic adverse events vs PBSC donors (0.99% vs 0.31%). Donors receiving granulocyte colony-stimulating factor for PBSC collection had no evidence of increased risk for cancer, autoimmune illness, and stroke.